A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma.
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2011
At a glance
- Drugs Temozolomide (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2011 New trial record